Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2023 | Utilizing novel biomarkers as treatment personalization tools in colorectal cancer

Filippo Pietrantonio • 22 Oct 2023
ESMO 2023
Colorectal Cancer Antibodies Atezolizumab Bevacizumab FOLFOXIRI
AtezoTRIBE

Filippo Pietrantonio, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses various biomarkers that will help to determine disease prognosis and allow for the development of personalized treatment strategies for patients with colorectal cancer. Dr Pietrantonio elaborates on some associated trials which have found these biomarkers to be of relevance. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Filippo Pietrantonio

Continued treatment with HER2-targeted therapies in patients with GEA
1:31
Continued treatment with HER2-targeted therapies in patients with GEA
Filippo Pietrantonio • 3 Jul 2026
HERIZON-GEA-01: response depth and PFS2 in HER2+ gastroesophageal cancer
4:14
HERIZON-GEA-01: response depth and PFS2 in HER2+ gastroesophageal cancer
Filippo Pietrantonio • 3 Jul 2026
ctDNA clearance as an early efficacy biomarker in KRAS G12C-mutated mCRC
2:04
ctDNA clearance as an early efficacy biomarker in KRAS G12C-mutated mCRC
Filippo Pietrantonio • 29 May 2026
SWOG S2107: encorafenib, cetuximab ± nivolumab in MSS BRAF V600E mCRC
1:32
SWOG S2107: encorafenib, cetuximab ± nivolumab in MSS BRAF V600E mCRC
Filippo Pietrantonio • 29 May 2026

Related Videos

POLE mutations as predictive biomarkers for immunotherapy in GI cancers
4:30
POLE mutations as predictive biomarkers for immunotherapy in GI cancers
Umair Mahmood • 16 Apr 2026
BATTMAN trial: botensilimab and balstilimab in MSS mCRC
1:14
BATTMAN trial: botensilimab and balstilimab in MSS mCRC
Benjamin Schlechter • 2 Jul 2026
Ablative treatment for colorectal liver metastases with curative intent: insights from CIEMAR
1:19
Ablative treatment for colorectal liver metastases with curative intent: insights from CIEMAR
Dirk Arnold • 10 Jul 2026
DEL-LIVER: percutaneous hepatic perfusion with melphalan for liver-dominant refractory mCRC
1:38
DEL-LIVER: percutaneous hepatic perfusion with melphalan for liver-dominant refractory mCRC
Dirk Arnold • 10 Jul 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals